Cargando…
Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
Initial reports of a clinical response in patients treated with the radioligand [(177)Lu]-PSMA-617 for castration-resistant prostate cancer (CRPC) are promising, despite known inter- and intrapatient heterogeneity. In metastatic CRPC, we examined the association of baseline immunohistochemical (IHC)...
Autores principales: | Stangl-Kremser, Judith, Rasul, Sazan, Tosoian, Jeffrey J., Salami, Simpa S., Zaslavsky, Alexander, Udager, Aaron, Mazal, Peter, Kain, Renate, Comperat, Eva, Hacker, Marcus, Haug, Alexander, Mitterhauser, Markus, Pozo-Salido, Carmen, Steinbach, Christina, Hassler, Melanie R., Kramer, Gero, Shariat, Shahrokh F., Palapattu, Ganesh S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317820/ https://www.ncbi.nlm.nih.gov/pubmed/34337549 http://dx.doi.org/10.1016/j.euros.2021.06.007 |
Ejemplares similares
-
Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
por: Rasul, Sazan, et al.
Publicado: (2019) -
Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
por: Zisser, Lucia, et al.
Publicado: (2022) -
Response and Toxicity to the Second Course of 3 Cycles of (177)Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Rasul, Sazan, et al.
Publicado: (2021) -
Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
por: Rasul, Sazan, et al.
Publicado: (2020) -
Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer
por: Rasul, Sazan, et al.
Publicado: (2022)